UO
University of Cambridge
University of Cambridge is a Series A to Series B stage investment firm. It has made 6 investments. 50% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Their most common stage is series-a (62% of deals).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
AM
Anne Marie Fleurbaaij
Managing Director, Marketable Assets
SS
Sam Sturge
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 T-Therapeutics | Series A | $91M | Nov 2025 |
| T-Therapeutics | Series A | — | Nov 2023 |
| T-Therapeutics | Series A | — | Jan 2023 |
| CCambridge Epigenetix | Series B | $21M | Jan 2016 |
| NNobacz Healthcare | Unknown | — | — |
 Echion Technologies | Series A | — | — |
 Nobacz | Unknown | — | — |
| EEchion | Series A | — | — |
Top Co-Investors
Cambridge Enterprise3 shared
BGF3 shared
Sanofi Ventures3 shared
F-Prime Capital3 shared
Fidelity Investments3 shared
Sofinnova Partners3 shared
Cambridge Innovation Capital3 shared
Digitalis Ventures3 shared
Adjuvo2 shared
Parkwalk Advisors2 shared
The Yield Lab2 shared
ACF Investors2 shared
Cambridge Angels2 shared
Origin Ventures2 shared
Sequoia Capital1 shared
CBMM1 shared
Barclays1 shared
Tencent Investment1 shared
Last updated: 19 September 2026